Molecular insights into substrate specificity of prostate specific antigen through structural modeling.
Prostate Specific Antigen's (PSA) role as a biomarker for prostate cancer is well established but the physiological role of its serine protease activity in the pathobiology of normal prostate and prostate carcinogenesis remains largely unknown. In light of recent studies that implicate PSA's enzymatic activity in the initiation and/or progression of prostate cancer, we performed a molecular modeling study of substrate binding at the catalytic site of PSA wherein a PSA-selective substrate (HSSKLQ) was docked in an acyl-enzyme conformation to a three-dimensional homology model of PSA. Additionally, virtual positional scanning studies were conducted to gain mechanistic insights into substrate recognition of PSA. Subsequently, 13 novel peptide substrates of 6-aa length and four peptide substrates with varying length were synthesized and assayed for PSA hydrolysis to evaluate the experimental validity of docking insights. Additionally, six novel aldehyde-containing transition state analog inhibitors were synthesized and tested for their inhibitory potencies. The experimental data on the hydrolysis rates of the newly synthesized substrates and inhibitory potencies of the aldehyde peptides agreed with the docking predictions, providing validation of the docking methodology and demonstrating its utility towards the design of substrate-mimetic inhibitors that can be used to explore PSA's role in the pathobiology of prostate cancer.
Singh
Pratap
P
Department of Chemical and Biomolecular Engineering, Johns Hopkins University Whiting School of Engineering, Baltimore, Maryland 21218, USA. psingh@jhu.edu
LeBeau
Aaron M
AM
Lilja
Hans
H
Denmeade
Samuel R
SR
Isaacs
John T
JT
D000465:Algorithms; D000595:Amino Acid Sequence; D020134:Catalytic Domain; D003198:Computer Simulation; D006801:Humans; D006868:Hydrolysis; D066298:In Vitro Techniques; D007700:Kinetics; D008024:Ligands; D008297:Male; D008958:Models, Molecular; D015394:Molecular Structure; D009842:Oligopeptides / Q000737:chemistry / Q000378:metabolism; D010446:Peptide Fragments / Q000737:chemistry / Q000378:metabolism; D017430:Prostate-Specific Antigen / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000378:metabolism*; D011487:Protein Conformation; D015842:Serine Proteinase Inhibitors / Q000737:chemistry / Q000494:pharmacology; D013379:Substrate Specificity
D008024:Ligands; D009842:Oligopeptides; D010446:Peptide Fragments; D015842:Serine Proteinase Inhibitors; D017430:Prostate-Specific Antigen
Biochemistry. 2001 Feb 27;40(8):2439-47
11327865
J Mol Biol. 1995 Jan 6;245(1):43-53
7823319
Nat Rev Cancer. 2004 Nov;4(11):876-90
15516960
Proc Natl Acad Sci U S A. 1986 May;83(10):3166-70
2422647
J Clin Endocrinol Metab. 1992 Oct;75(4):1046-53
1383255
Cancer Res. 2004 Dec 15;64(24):9209-16
15604294
J Pept Res. 1999 Oct;54(4):319-27
10532237
J Pept Sci. 2005 Sep;11(9):525-35
16001455
Nihon Hoigaku Zasshi. 1971 Jul;25(4):322-4
5106556
J Mol Biol. 2004 Dec 3;344(4):1005-20
15544809
J Biol Chem. 1997 Nov 28;272(48):29987-90
9374470
Chem Biol. 1998 Sep;5(9):475-88
9751643
Nat Med. 1995 Sep;1(9):944-9
7585222
Biochem Biophys Res Commun. 1993 Apr 30;192(2):940-7
7683467
Acta Biochim Pol. 2001;48(2):419-28
11732612
Prostate. 2000 Oct 1;45(2):132-9
11027412
Cell Tissue Res. 2005 Oct;322(1):43-52
15909166
Science. 1998 Jan 23;279(5350):563-6
9438850
J Mol Biol. 1997 Apr 4;267(3):727-48
9126849
Cancer Res. 1997 Nov 1;57(21):4924-30
9354459
Proteins. 2008 Mar;70(4):1416-28
17894328
Biochemistry. 1998 Sep 1;37(35):12094-103
9724521
Chem Biol. 2008 Jul 21;15(7):665-74
18635003
J Clin Invest. 1985 Nov;76(5):1899-903
3902893
J Pept Res. 2004 Feb;63(2):69-84
15009528
Biochemistry. 2001 Oct 2;40(39):11734-41
11570874
Prostate. 2007 Feb 15;67(3):312-29
17143882
Protein Sci. 1995 Mar;4(3):337-60
7795518
J Biol Chem. 2006 Sep 1;281(35):25678-88
16740631
Protein Sci. 1994 Nov;3(11):2033-44
7535613